Elanco Animal Health Incorporated Common Stock (ELAN) — Analysis Summary
Elanco Animal Health Incorporated Common Stock (ELAN) has a market cap of $11.57B with year-over-year revenue growth of +6.2%. Net margin stands at -4.9%. The stock trades at a P/E ratio of -58.1.
Key Takeaways
- Revenue changed +6.2% year-over-year
- Net margin of -4.9%
- P/E ratio of -58.1
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ELAN posted revenue growth of +6.2% and trades at a P/E of -58.1.
Elanco Animal Health Incorporated Common Stock (ELAN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.0x — earnings do not cover interest payments
Debt/EBITDA at 5.1x — elevated leverage
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
9,900
Headquarters
INDIANAPOLIS, IN
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.